Posted by Michael Wonder on 10 Oct 2019
Biosimilars in the UK: where are we now and where does the NHS want to go?
9 October 2019 - The UK health service has well over a decade’s experience of dealing with biosimilars, but the NHS acknowledges that it has yet to make the most of these drugs.
That was certainly one of the messages from a ‘state of the biosimilar nation’ event I attended over the summer in London, and it’s not a surprising one.
The first European biosimilar approval in 2006 for a version of a human growth hormone was, to some extent, a false dawn for the sector, in as much as it didn’t pique widespread financial interest from health care stakeholders.
